Executive Summary
Summary of QQ3 2024 results for Cardinal Health shows revenue resilience amid ongoing margin pressures and liquidity considerations. The quarter delivered revenue of $54.868 billion with gross profit of $1.935 billion, yielding a gross margin of approximately 3.4% and an operating margin around 0.7%. Net income of $261 million and earnings per share (EPS) of $1.07 reflect modest profitability in a highly competitive healthcare distribution landscape. Year-over-year (YoY) revenue rose about 8.7%, but both operating income and net income declined on a relative basis, with QoQ declines also evident, underscoring margin compression and cost dynamics affecting profit translation.
Balance sheet and cash flow metrics reveal a cash-rich balance sheet but a structurally leveraged equity position. The company holds cash and cash equivalents of $3.72 billion and reports net debt of roughly $2.14 billion, while total liabilities exceed assets by about $4.26 billion, resulting in negative stockholders’ equity (~$-3.27 billion). Operating cash flow was negative in the quarter (-$49 million) and free cash flow was also negative (-$161 million), driven by working capital changes (-$588 million) and capital expenditures of $112 million. Financing activities provided liquidity (~$1.03 billion), contributing to overall liquidity management. Payout ratio stands at 47.3%, signaling a relatively income-focused dividend policy amid the balance sheet dynamics.
Looking ahead, the near-term outlook remains a function of ongoing margin discipline, working capital optimization, and balance sheet restructuring. The competitive and regulatory environment in healthcare distribution remains challenging, with limited visibility on explicit forward guidance in the provided data. Investors should monitor margin stabilization, cash flow generation, and deleveraging progress, alongside portfolio optimization initiatives that could unlock earnings upside over time.
Key Performance Indicators
QoQ: -26.93% | YoY:-35.49%
QoQ: -29.08% | YoY:-24.35%
QoQ: -28.67% | YoY:-20.74%
Key Insights
Revenue: $54.868 billion; YoY +8.68%, QoQ -4.48%
Gross Profit: $1.935 billion; YoY +8.40%, QoQ +4.82%; Gross Margin ~3.43%
Operating Income: $369 million; YoY -35.49%, QoQ -26.93%; Operating Margin ~0.67%
Net Income: $261 million; YoY -24.35%, QoQ -29.08%; Net Margin ~0.47%
EPS: $1.07; YoY -20.74%, QoQ -28.67%
Balance Sheet Health: Total assets $45.88B; Total liabilities $49.14B; Stockholders’ equity -$3.27B
Liquidity: Cash & equivalents $3.72B; Net debt $2.14B; Current ratio 0.98; Quick r...
Financial Highlights
Revenue: $54.868 billion; YoY +8.68%, QoQ -4.48%
Gross Profit: $1.935 billion; YoY +8.40%, QoQ +4.82%; Gross Margin ~3.43%
Operating Income: $369 million; YoY -35.49%, QoQ -26.93%; Operating Margin ~0.67%
Net Income: $261 million; YoY -24.35%, QoQ -29.08%; Net Margin ~0.47%
EPS: $1.07; YoY -20.74%, QoQ -28.67%
Balance Sheet Health: Total assets $45.88B; Total liabilities $49.14B; Stockholders’ equity -$3.27B
Liquidity: Cash & equivalents $3.72B; Net debt $2.14B; Current ratio 0.98; Quick ratio 0.51; Cash ratio 0.10
Cash Flow: Operating cash flow -$49M; Free cash flow -$161M; Change in working capital -$588M; CAPEX $112M; Net cash from financing activities +$1.031B; Net cash change -$0.873B; Cash at end $3.718B
Efficiency: DSO 18.96 days; DIO 29.32 days; DPO 54.46 days; CCC -6.18 days
Valuation/Returns: ROE -7.90%; ROA 0.56%; ROCE 6.28%; P/E ~26.0x; P/B negative (due to negative equity); Dividend Payout ~47.3%
Income Statement
| Metric |
Value |
YoY Change |
QoQ Change |
| Revenue |
54.87B |
8.68% |
-4.48% |
| Gross Profit |
1.94B |
8.40% |
4.82% |
| Operating Income |
369.00M |
-35.49% |
-26.93% |
| Net Income |
261.00M |
-24.35% |
-29.08% |
| EPS |
1.07 |
-20.74% |
-28.67% |
Key Financial Ratios
operatingProfitMargin
1.09%
operatingCashFlowPerShare
$-0.2
freeCashFlowPerShare
$-0.66
dividendPayoutRatio
47.3%
Management Commentary
No earnings call transcript data provided for QQ3 2024. When available, management highlights would typically cover strategy execution (cost discipline, pricing, and mix), operating efficiency (working capital management, supply chain optimization), market conditions (volume trends in hospitals/pharmacies), and capital allocation (dividend policy, debt levels, potential share repurchases). Given the data, no direct quotes can be cited.
Forward Guidance
No explicit forward guidance is included in the provided data for QQ3 2024. Given the margin compression and negative free cash flow, investors should expect management to emphasize cost control, working capital optimization, and balance sheet deleveraging efforts. Key factors to monitor include: sustainability of revenue growth drivers, progress on margin expansion initiatives, cash flow recovery, and any capital allocation changes (dividends, buybacks, or strategic investments).